The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM).
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Abbvie; Adagene; Bayer; BMS; Delcath Systems; Eisai; Entos; Janssen Research & Development; Merck; Microbial Machines; Mirati Therapeutics; Nouscom; Pfizer; Roche/Genentech; Taiho Pharmaceutical; Tempus; Totus Medicines
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst)
 
Neil Segal
Consulting or Advisory Role - Agenus; AstraZeneca; Novartis; Numab; PureTech; regeneron
Research Funding - Agenus (Inst); AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer; PureTech (Inst); Regeneron (Inst); Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Regeneron
 
Benjamin Schlechter
Consulting or Advisory Role - Agenus; Janssen; Quercegen Pharmaceuticals
 
Thierry Andre
Honoraria - Bristol-Myers Squibb; Merck; Merck Serono; Sanofi; Seagen; SERVIER
Consulting or Advisory Role - Abbvie; Aptitude Health; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; MSD Oncology; Nimbus Therapeutics; Nordic Bioscience; Pfizer; Seagen; SERVIER; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; Takeda
Other Relationship - Inspirna
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; ARCAD Foundation
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Merck Serono; Pierre Fabre; Takeda Science Foundation
 
Benny Johnson
Stock and Other Ownership Interests - Agenus
Consulting or Advisory Role - Gritstone Bio; Incyte; Insmed; Iota Biosciences; Pfizer; Taiho Oncology
Research Funding - Bristol-Myers Squibb (Inst); Gateway Foundation (Inst); Syntrix Biosystems (Inst)
 
Alexander Vasilyev
No Relationships to Disclose
 
Smitha Krishnamurthi
Consulting or Advisory Role - Agenus; Bristol-Myers Squibb; Takeda
Research Funding - Agenus (Inst); Aravive (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for two chapters I have written in UptoDate
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Agenus; AstraZeneca; Bayer; Bristol-Myers Squibb; CheckmAb; Daiichi Sankyo; GlaxoSmithKline; Merck; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Seagen; T-One Therapeutics
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Wells Messersmith
Honoraria - Research to Practice (Inst)
Consulting or Advisory Role - Amgen; Criterium (Inst)
Research Funding - Agenus (Inst); ALX Oncology (Inst); AstraZeneca/MedImmune (I); Beigene (Inst); CanBas (Inst); Exelixis (Inst); Experimental Drug Development Centre (EDDC); FATE Therapeutics (Inst); Mirati Therapeutics (Inst); Nurix (Inst); Pfizer (Inst); PureTech (Inst); RasCal (Inst); Revolution Medicines (Inst)
 
Virgilio Souza E Silva
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Merck KGaA; Merck Sharp & Dohme; Pfizer; SERVIER
 
Andrew Paulson
Employment - Day One Biopharmaceuticals (I)
Stock and Other Ownership Interests - Actinium Pharmaceuticals
Honoraria - Array BioPharma; Cardinal Health; Curio Science
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Agenus; Amgen; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; Eisai; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Hutchison MediPharma; Incyte; Ipsen; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Novartis; Pfizer; QED Therapeutics; Seagen; SERVIER; Stromatis Pharma; Takeda
Speakers' Bureau - Ideo Oncology
Research Funding - AstraZeneca (Inst); Bayer (Inst); BioNTech SE (Inst); bristol myers squibb (Inst); Buzzard Pharmaceuticals; Camurus (Inst); Camurus (Inst); Deciphera (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); incyte (Inst); Innovative Cellular Therapeutics Co (Inst); Inspirna (Inst); Ipsen (Inst); ITM Oncologics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Regenxbio (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tempus (Inst); TransThera Biosciences (Inst); Zentalis (Inst)
Travel, Accommodations, Expenses - AADi; Camurus; Mirati Therapeutics; Nucana; Pfizer
 
Elena Elez
Honoraria - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; Janssen; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Roche; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech (Inst); Biontech Rna Pharmaceuticals GMBH (Inst); Biontech Small Molecules GMBH (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim Spain (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Inc. (Inst); Debiopharm Group (Inst); Genentech (Inst); Gercor (Inst); HalioDx (Inst); Hoffmann-La-Roche Ltd. (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom SRL. (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharma USA (Inst); Taiho Pharmaceutical (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi; Seagan; SERVIER; Takeda
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Amgen (I); California Institute for Regenerative Medicine (CIRM) (I); Hookipa Biotech; IgM Biosciences (I); Merck Serono; Pfizer; Seagen; Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Takeda
 
Sabine Tejpar
Honoraria - Merck Serono; Regeneron
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Merck Serono; Regeneron; Roche/Genentech
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD; Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Serono; Roche; Sanofi
 
Michel Ducreux
Employment - Sandoz (I)
Honoraria - Bayer; Pierre Fabre; Roche/Genentech; TERUMO
Consulting or Advisory Role - Abbvie (Inst); Abcely; Amgen; Astellas Pharma; AstraZeneca; Basilea; Bayer; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; HalioDx; Ipsen; Lilly; Merck Serono; MSD; Novartis; Pierre Fabre; Rafael Pharmaceuticals; Roche; Scandion Oncology; Servier; Sotio; Zymeworks
Speakers' Bureau - Amgen; AstraZeneca; Bayer; GlaxoSmithKline; HalioDx; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; SERVIER
Research Funding - Keocyt (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Serono; Pierre Fabre; Roche; SERVIER
 
Wei Wu
Employment - Agenus
Stock and Other Ownership Interests - Agenus
 
Joseph Grossman
Employment - Agenus
Stock and Other Ownership Interests - Agenus
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; GlaxoSmithKline; Hookipa Biotech; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; TERUMO
 
Manuel Hidalgo
Leadership - BMS
Stock and Other Ownership Interests - Champions Oncology; InxMed; Nelum Corp.
Honoraria - Champions Oncology; InxMed; MiNK Therapeutics; Oncomatrix
Consulting or Advisory Role - Fibrogen; InxMed; KAHR Medical; MiNK Therapeutics; Oncomatrix
Research Funding - Ranok Therapeutics; TopAl
Patents, Royalties, Other Intellectual Property - Royalties from Khar Medical for IP in cell therapy; Royalties from Myriad for PALB2 patent
Travel, Accommodations, Expenses - Agenus